DiaMedica Therapeutics Inc.

NASDAQ•DMAC

CEO: Mr. Dietrich John Pauls MBA

セクター: Healthcare

業種: Biotechnology

上場日: 2012-08-03

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

連絡先情報

301 Carlson Parkway, Suite 210, Minneapolis, MN, 55305, United States

(763)-496-5454

www.diamedica.com

時価総額

$370.79M

PER (TTM)

-11.1

17.6

配当利回り

52週高値

$10.42

52週安値

$3.19

52週レンジ

54%

順位62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.9 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.17+13.33%

直近4四半期の推移

フリーCF

-$6.62M+47.82%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Cash Position Strengthened Combined cash, equivalents, and securities total $55.3M as of September 30, 2025, up from $44.1M year-end 2024.

July Private Placement Closed Raised $30.0M net proceeds in July 2025 private placement, funding operations and clinical expansion efforts.

PE Trial Interim Results Investigator-sponsored PE Phase 2 Part 1a showed DM199 safe, well-tolerated with sustained blood pressure reduction.

リスク要因

Operating Cash Burn Widens Net cash used in operating activities increased to $(21.3)M for nine months 2025 versus $(15.6)M prior year.

AIS Trial Enrollment Slow ReMEDy2 trial faces slower site activations and enrollment due to staffing shortages and protocol complexity.

Significant Future Capital Needed Expect substantial additional capital required to complete required clinical studies and achieve commercialization milestones.

見通し

Key Clinical Milestones Targeted Planning FPI for PE Part 1b in 1H 2026; anticipating AIS ReMEDy2 interim analysis in 2H 2026.

R&D Spending Expected Rise R&D expenses expected to moderately increase as DM199 program advances into PE and global ReMEDy2 expansion.

ATM Offering Available $98.4M remains available under the August 2025 At-The-Market offering program for future capital needs.

同業比較

売上高 (TTM)

HUMA

$8.80M

+0.0%

KRRO

$6.39M

+181.5%

DBVT

$511.00K

-95.5%

粗利益率 (最新四半期)

ALT

100.0%

-299200.0pp

HUMA

65.5%

+0.0pp

KRRO

49.8%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANNX	$648.21M	-3.9	-92.3%	11.8%
DRTS	$623.28M	-14.7	-57.3%	12.9%
DSGN	$586.73M	-8.5	-32.7%	0.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月31日

EPS:-$0.18

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし